Biosign Certified for Non-invasive Blood Glucose Monitoring

Toronto (ots/PRNewswire) - Biosign Technologies Inc. (CNSX:
BIO) ("Biosign" or the "Company") today announced it has been
assessed and certified as meeting the requirements of ISO 9001:2008,
ISO 13485-2003, and Directive 93/42/EEC ("CE Mark") for automated
wrist blood pressure and blood glucose monitors with computer
controls. The certificates allow Biosign to add non-invasive blood
glucose monitoring to its offerings in the European Union and other
regions that recognize these certifications.

Practically, UFIT(R) TEN-20 is a blood pressure monitor that also
reads blood glucose. There is no additional hardware. Measurements
are completely non-invasive, with results verifiable for accuracy and
relevance.

"Researchers have attempted for years to find a solution that can
eliminate the need for pricking the skin and drawing blood to measure
glucose levels", said Peter Tassiopoulos, Biosign's Chief Operating
Officer. "UFIT(R) TEN-20 solves this issue and, more importantly, it
keeps an audit trail of every measurement taken for future
reference."

The company is scaling resources for support and manufacturing to
prepare for the anticipated demand by the market for the newly
certified capability of the UFIT(R) system. "We can now proceed
confidently on executing our ambitious plans for 2010." said Radu
Leca, President and CEO of Biosign.

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include
intelligent systems for noninvasive monitoring of common health risks
associated with blood pressure, glucose, and medication. The core
technology combines measurement, analysis, and rapid knowledge
formation to support health monitoring across global markets. The
UFIT(R) medical device technology powers quality data collection and
analytics for clinical diagnostics, self-care, wellness, disease
state evaluation & management, and remote patient monitoring. For
more information on Biosign please visit http://www.biosign.com

The CNSX has neither approved nor disapproved the contents of
this press release.

For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., +1-416-218-9800 ext. 234, ceo@biosign.com

ots Originaltext: Biosign Technologies Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: Radu Leca, President & CEO,
BiosignTechnologies Inc., +1-416-218-9800 ext. 234, ceo@biosign.com